Company Filing History:
Years Active: 2024
Title: Sneha Ramakrishna: Innovator in Monoclonal Antibody Development
Introduction
Sneha Ramakrishna is a prominent inventor based in Bethesda, MD, who has made significant contributions to the field of biotechnology. She is known for her innovative work in developing monoclonal antibodies, which play a crucial role in the treatment of various diseases, particularly B-cell malignancies.
Latest Patents
Sneha holds a patent for an affinity matured CD22-specific monoclonal antibody and its uses. This groundbreaking invention describes an affinity matured anti-CD22 human monoclonal antibody that exhibits significantly higher affinity, less than 50 pM, compared to the parental antibody, which has an affinity of about 2 nM. The anti-CD22 variant antibody or a fragment thereof, such as a single-chain variable fragment (scFv), can be utilized as the antigen-binding portion of chimeric antigen receptors (CARs), antibody-drug conjugates (ADCs), immunotoxins, or multi-specific antibodies for the treatment of B-cell malignancies.
Career Highlights
Sneha is currently employed at the National Institutes of Health, a component of the US Department of Health & Human Services. Her work at this prestigious institution allows her to collaborate with leading experts in the field and contribute to groundbreaking research that has the potential to improve patient outcomes.
Collaborations
Some of her notable coworkers include Dimiter Stanchev Dimitrov and Zhongyu Zhu, who are also involved in advancing research in the field of monoclonal antibodies and related therapies.
Conclusion
Sneha Ramakrishna's innovative work in the development of monoclonal antibodies exemplifies her commitment to advancing medical science. Her contributions have the potential to significantly impact the treatment of B-cell malignancies and improve the lives of many patients.